Evolution in the treatment of metastatic colorectal carcinoma of the liver.
Metastatic colorectal cancer to the liver is associated with a uniform poor prognosis without treatment. Advances in therapy over the past decades have now allowed surgical resections of the liver to occur with a low morbidity and mortality. Improvements in chemotherapy regimes have paralleled technical improvements and now allow a new group of patients to become eligible for surgical resection. This chapter will review the recent advances in surgical and chemotherapeutic regimes in metastatic colorectal cancer to the liver.
Ariyan
Charlotte-E
CE
Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, Tompkins 202, 333 Cedar Street, New Haven, CT 06520, USA.
Salem
Ronald-R
RR
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D008099:Liver / Q000187:drug effects / Q000601:surgery; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D008297:Male; D020360:Neoadjuvant Therapy; D011379:Prognosis
D000970:Antineoplastic Agents